Search the Newsreel

Third Rock Ventures V, L.P. director sells $7.4m Septerna shares

Third Rock Ventures V, L.P., a significant shareholder and director of Septerna, Inc., sold 147,200 shares of the company's common stock for approximately $7.4 million on August 12, 2026. The sales were executed through a pre-arranged trading plan, with shares trading near their 52-week …

Form 4: Third Rock Ventures reports acquisition/exercise transactions in SEPN

Third Rock Ventures V, L.P. reported insider transactions in Septerna, Inc. (SEPN) through a Form 4 filing, indicating sales of 147,200 shares at a weighted average price of $50.27 per share. These transactions, executed on August 12, 2026, were conducted under a Rule 10b5-1 …

Septerna (SEPN): RA Capital funds disclose sale of 1.49M common shares

RA Capital Healthcare Fund LP and RA Capital Nexus Fund III, L.P. reported the sale of 1,493,000 common shares of Septerna, Inc. (SEPN) on August 12, 2026, at a price of $42.50 per share. The sales were made by affiliated entities of RA Capital, …

RA Capital group (SEPN) discloses 11.8% Septerna stake and major block sales

RA Capital Management and its associated entities have disclosed a beneficial ownership of 11.8% in Septerna, Inc. (SEPN), totaling 5,525,324 shares. This updated filing, a Schedule 13D/A, details holdings across various funds and includes significant block sales made on August 12, 2026, where RA …

HC Wainwright Predicts Septerna's Q3 Earnings (NASDAQ:SEPN)

Septerna (SEPN) President & COO exercises 25,000 options and sells shares under 10b5-1 plan

Septerna, Inc. President and COO Elizabeth Bhatt exercised 25,000 stock options on August 11, 2026, with exercise prices of $6.81 for 18,681 shares and $2.76 for 6,319 shares. On the same day, she sold all 25,000 Common Stock shares at $44.00 per share. This …

Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 25,000 Shares of Stock

Septerna president & COO Elizabeth Bhatt disposes of $1.1m in stock

Elizabeth Bhatt, President and COO of Septerna, Inc. (NASDAQ:SEPN), sold 25,000 shares of common stock for $1.1 million on August 11, 2026, after acquiring them through stock option exercises. These transactions were executed under a Rule 10b5-1 sales plan, leaving Bhatt with 174,209 directly …

JonesTrading Forecasts Strong Price Appreciation for Septerna (NASDAQ:SEPN) Stock

SEPN (SEPN) plans NASDAQ sale of 746,500 shares worth $35.97M

Septerna, Inc. (SEPN) has filed a Form 144 indicating its intent to sell 746,500 common shares on NASDAQ through broker BTIG LLC, with an aggregate market value of $35,973,835.00. These shares were acquired in two blocks in May and October 2024 through IPO settlement …

Septerna, Inc. SEC Filing (Aug 12, 2026)

Septerna, Inc. has filed a Form 144 with the SEC on August 12, 2026, indicating a proposed sale of securities. The filing details the sale of 746,500 common shares acquired through an IPO on October 25, 2024, with an aggregate market value of $35,973,835.00, …

Does Septerna (SEPN) Pair Narrowing Losses With A Cash Runway That Truly Supports Its Pipeline Strategy?

Septerna, Inc. reported narrowing net losses and increased sales in Q2 2026, driven by a collaboration with Novo Nordisk. The company reiterated its cash runway into 2029, supporting its early-stage clinical pipeline. Despite positive financial updates, the article notes ongoing concerns regarding Septerna's valuation …

Septerna Inc stock hits all-time high at 50.0 USD By Investing.com

Septerna Inc (SEPN) stock has reached an all-time high of $50, currently trading at $49.47 with a market capitalization of $2.28 billion, reflecting a 326% increase over the past year. InvestingPro analysis suggests the stock is fairly valued, with significant momentum highlighted by a …

H.C. Wainwright raises Septerna stock price target to $60 on SEP-479 progress

H.C. Wainwright increased its price target for Septerna Inc (NASDAQ:SEPN) to $60 from $40, maintaining a Buy rating, due to positive progress in the Phase 1 trial of SEP-479 for hypoparathyroidism. The drug shows a favorable pharmacokinetic profile supporting once-daily dosing, with full Phase …

Septerna Shares (SEPN) Surge 23% Following Positive SEP-479 Signal, Exceeding Analyst Predictions

Septerna, Inc. Stock 12‑Month Price Target Raised to $47, Implies 21% Upside

Septerna, Inc.'s average 12-month price target has been increased from $45 to $47 by 9 analysts, with individual forecasts ranging from $38 to $60 per share. This new target suggests a potential upside of approximately 21% based on the August 10 closing price. The …

Seer (SEPN) insiders plan sale of 29,000 shares after option exercise

Seer, Inc. (SEPN) has filed a Form 144 notice to allow the potential sale of 29,000 common shares by an affiliate, following an option exercise on August 11, 2026, valued at $1,126,650.00. The filing also disclosed a previous sale of 4,000 shares on July …

Raymond James Maintains Septerna(SEPN.US) With Buy Rating, Cuts Target Price to $49

Raymond James has reiterated its Buy rating for Septerna (SEPN.US) but has adjusted its price target downwards to $49. This indicates a continued positive outlook on the company's prospects despite a revision in the expected share price. Investors may see this as a signal …

Septerna (NASDAQ:SEPN) Stock Price Up 9% Following Earnings Beat

Septerna (NASDAQ:SEPN) shares rose 9% after reporting better-than-expected quarterly earnings, with an EPS of negative $0.29 against estimates of negative $0.43, and revenue of $26.75 million exceeding the $19.22 million consensus. Despite broad analyst positivity and a "Moderate Buy" consensus rating, the company remains …

Stifel raises Septerna stock price target to $49 on SEP-479 outlook

Stifel has increased its price target for Septerna Inc. (NASDAQ:SEPN) to $49 from $43, maintaining a Buy rating due to an improved outlook for SEP-479, a hypoparathyroidism drug. The firm raised the drug's probability of success to 50% from 33% based on positive preclinical …

Guggenheim raises Septerna stock price target to $51 on pipeline progress

Guggenheim has increased its price target for Septerna Inc. (NASDAQ:SEPN) to $51 from $45, maintaining a Buy rating, due to pipeline progress and an increased probability of success for its drug candidate SEP-479. The company is also exploring new indications for SEP-631 and expects …

Septerna (NASDAQ:SEPN) Hits New 1-Year High - Still a Buy?

Septerna (NASDAQ:SEPN) recently hit a new 52-week high of $40.65, trading around $38.26, significantly above its moving averages. The clinical-stage biotech reported better-than-expected quarterly earnings, with a loss of $0.19 per share against an anticipated $0.42 loss, and revenues of $26.52 million, exceeding estimates …

Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates

Septerna, Inc. (SEPN) reported a Q2 loss of $0.29 per share, beating the Zacks Consensus Estimate of a $0.48 loss and surpassing last year's $0.56 loss. The company's revenues for the quarter reached $26.75 million, significantly exceeding the Zacks Consensus Estimate by 30.07%. Despite …

Earnings Flash (SEPN) Septerna, Inc. Reports Q2 Revenue $26.7M, vs. FactSet Est of $19.2M

Septerna, Inc. (SEPN) reported its second-quarter revenue of $26.7 million, significantly surpassing FactSet's estimate of $19.2 million. This financial news also notes that the company's Q2 loss per share narrowed to $0.29, compared to an estimated loss of $0.43. Septerna is a clinical-stage biotechnology …

Septerna (NASDAQ:SEPN) Releases Earnings Results, Beats Expectations By $0.14 EPS

Septerna (NASDAQ:SEPN) announced its latest earnings results, reporting an adjusted loss of $0.29 per share, which beat analyst expectations by $0.14. The company's revenue also surpassed estimates, reaching $26.75 million against a consensus of $19.22 million. Despite strong financial performance and a "Moderate Buy" …

Septerna Q2 Results: Sales surge 22,380% YoY to $26.746M

Septerna reported a significant revenue surge to $26.7 million in Q2 2026, primarily due to its collaboration with Novo Nordisk, a dramatic increase from $0.1 million in Q2 2025. The company also narrowed its net loss to $13.0 million and maintains a strong cash …

Septerna (SEPN) boosts collaboration revenue and extends cash runway into 2029

Price to book forward of Septerna, Inc. – NASDAQ:SEPN

The article focuses on the "Price to book forward" metric for Septerna, Inc. (NASDAQ: SEPN). It indicates that the company is listed on the Nasdaq Stock Market and provides information about its financial data, market status, and other related details through the TradingView platform.

ETFs Investing in Septerna, Inc. Stocks

This article lists various ETFs that currently hold stocks of Septerna, Inc. (SEPN). The ETFs are sorted by market value and include details such as issuer, management style, focus, expense ratio, and assets under management. The information aims to help investors find accessible and …

Septerna (NASDAQ:SEPN) SVP Sells $114,922.98 in Stock

Septerna (NASDAQ:SEPN) SVP Daniel Long sold 3,334 shares of the company's stock for $114,922.98 on August 3rd, 2026, reducing his ownership by 3.34% to 96,412 shares valued at approximately $3.32 million. The company's stock is trading near its 52-week high, with a market capitalization …

Septerna (SEPN) SVP exercises options and sells 3,334 shares under plan

Daniel D. Long, SVP of Drug Discovery at Septerna (SEPN), exercised stock options for 3,334 shares of common stock at $2.76 per share and subsequently sold all 3,334 shares on August 3, 2026. The sales were executed in two blocks at weighted average prices …

Septerna Inc stock hits all-time high at 38.21 USD By Investing.com

Septerna Inc. (SEPN) stock reached an all-time high of $38.21, reflecting a 221.8% increase over the past year and strong investor confidence. Despite being considered overvalued by some metrics, analysts maintain bullish price targets, with several firms reiterating Buy ratings and raising price targets …

Septerna (SEPN) Projected to Post Quarterly Earnings on Monday